Product References
α-Fetoprotein contributes to the malignant biological properties of AFP-producing gastric cancer.
Open life sciences
Mao X,Wang J,Luo F
37-0100 was used in Immunohistochemistry to suggest that AFP contributes to the malignant biological properties of AFP-GC and the high expression of c-Met in AFP-GC.
Fri Aug 18 00:00:00 EDT 2023
α-Fetoprotein contributes to the malignant biological properties of AFP-producing gastric cancer.
Open life sciences
Mao X,Wang J,Luo F
37-0100 was used in Immunohistochemistry to suggest that AFP contributes to the malignant biological properties of AFP-GC and the high expression of c-Met in AFP-GC.
Fri Aug 18 00:00:00 EDT 2023
Alpha-fetoprotein can promote gastric cancer progression via upregulation of metastasis-associated colon cancer 1.
Oncology letters
Mao X,Wang J,Luo F
37-0100 was used in Western Blot to investigate the interaction between alpha-fetoprotein and metastasis-associated colon cancer 1.
Tue Mar 01 00:00:00 EST 2022
Dimerization of kringle 1 domain from hepatocyte growth factor/scatter factor provides a potent MET receptor agonist.
Life science alliance
de Nola G,Leclercq B,Mougel A,Taront S,Simonneau C,Forneris F,Adriaenssens E,Drobecq H,Iamele L,Dubuquoy L,Melnyk O,Gherardi E,de Jonge H,Vicogne J
37-0100 was used in Western Blotting to describe the rational design, production, and characterization of K1K1, a novel minimal MET agonist consisting of two copies of the kringle 1 domain of Hepatocyte growth factor/scatter factor in tandem orientation.
Fri Jul 29 00:00:00 EDT 2022
Dimerization of kringle 1 domain from hepatocyte growth factor/scatter factor provides a potent MET receptor agonist.
Life science alliance
de Nola G,Leclercq B,Mougel A,Taront S,Simonneau C,Forneris F,Adriaenssens E,Drobecq H,Iamele L,Dubuquoy L,Melnyk O,Gherardi E,de Jonge H,Vicogne J
37-0100 was used in Western Blotting to describe the rational design, production, and characterization of K1K1, a novel minimal MET agonist consisting of two copies of the kringle 1 domain of Hepatocyte growth factor/scatter factor in tandem orientation.
Fri Jul 29 00:00:00 EDT 2022
A novel agonist for the HGF receptor MET promotes differentiation of human pluripotent stem cells into hepatocyte-like cells.
Development, growth & differentiation
Tauran Y,Lereau-Bernier M,Segard BD,Danoy M,Kimura K,Shinohara M,Brioude A,Sakai Y,de Jonge H,Melnyk O,Vicogne J,Leclerc E
37-0100 was used in Western Blotting to analyse levels of hepatocyte markers to show typical liver mRNA and protein expression (HNF4α, albumin, alpha-fetoprotein, CYP3A4) and phenotypes. Although full maturation was not achieved, the results suggest that K1K1 is an attractive candidate MET agonist suitable for replacing complex and expensive HGF treatments to induce hepatic differentiation of hiPSCs.
Thu Dec 01 00:00:00 EST 2022
A novel agonist for the HGF receptor MET promotes differentiation of human pluripotent stem cells into hepatocyte-like cells.
Development, growth & differentiation
Tauran Y,Lereau-Bernier M,Segard BD,Danoy M,Kimura K,Shinohara M,Brioude A,Sakai Y,de Jonge H,Melnyk O,Vicogne J,Leclerc E
37-0100 was used in Western Blotting to analyse levels of hepatocyte markers to show typical liver mRNA and protein expression (HNF4α, albumin, alpha-fetoprotein, CYP3A4) and phenotypes. Although full maturation was not achieved, the results suggest that K1K1 is an attractive candidate MET agonist suitable for replacing complex and expensive HGF treatments to induce hepatic differentiation of hiPSCs.
Thu Dec 01 00:00:00 EST 2022
Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma.
Cell reports. Medicine
Hagege A,Saada-Bouzid E,Ambrosetti D,Rastoin O,Boyer J,He X,Rousset J,Montemagno C,Doyen J,Pedeutour F,Parola J,Bourget I,Luciano F,Bozec A,Cao Y,Pagès G,Dufies M
37-0100 was used in Western Blot to demonstrate that cabozantinib, an inhibitor of vascular endothelial growth factor receptor (VEGFR), c-MET, and AXL, decreases migration, invasion, and proliferation and induces mitotic catastrophe and apoptotic cell death of naive and radiotherapy- and cisplatin-resistant HNSCC cells.
Tue Sep 20 00:00:00 EDT 2022
Down-regulation of the tumor suppressor miR-34a contributes to head and neck cancer by up-regulating the MET oncogene and modulating tumor immune evasion.
Journal of experimental & clinical cancer research : CR
Wu X,Cheng YL,Matthen M,Yoon A,Schwartz GK,Bala S,Taylor AM,Momen-Heravi F
37-0100 was used in Flow Cytometry to demonstrate that miR-34a directly targets MET and maintains anti-tumor immune activity. We propose miR-34a as a potential new therapeutic approach for HNSCC.
Wed Feb 17 00:00:00 EST 2021
Targeting the MET Receptor Tyrosine Kinase as a Strategy for Radiosensitization in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma.
Molecular cancer therapeutics
Nisa L,Francica P,Giger R,Medo M,Elicin O,Friese-Hamim M,Wilm C,Stroh C,Bojaxhiu B,Quintin A,Caversaccio MD,Dettmer MS,Buchwalder M,Brodie TM,Aebersold DM,Zimmer Y,Carey TE,Medová M
37-0100 was used in Immunohistochemistry to assess MET expression and mutation status in lesions of those with head and neck squamous cell carcinoma.
Sat Feb 01 00:00:00 EST 2020
A cysteine selenosulfide redox switch for protein chemical synthesis.
Nature communications
Diemer V,Ollivier N,Leclercq B,Drobecq H,Vicogne J,Agouridas V,Melnyk O
37-0100 was used in Western Blotting to show reduction of the selenosulfide bond in N-selenoethyl cysteine causes it to lose its selenoethyl arm in water under mild conditions.
Fri May 22 00:00:00 EDT 2020
A cysteine selenosulfide redox switch for protein chemical synthesis.
Nature communications
Diemer V,Ollivier N,Leclercq B,Drobecq H,Vicogne J,Agouridas V,Melnyk O
37-0100 was used in Western Blotting to show reduction of the selenosulfide bond in N-selenoethyl cysteine causes it to lose its selenoethyl arm in water under mild conditions.
Fri May 22 00:00:00 EDT 2020
Control of cell death/survival balance by the MET dependence receptor.
eLife
Duplaquet L,Leroy C,Vinchent A,Paget S,Lefebvre J,Vanden Abeele F,Lancel S,Giffard F,Paumelle R,Bidaux G,Heliot L,Poulain L,Furlan A,Tulasne D
37-0100 was used in Western Blotting to shed light on new signaling mechanisms for dependence receptors' control of cell survival/death balance, which may offer new clues for the pathophysiology of epithelial structures.
Mon Feb 24 00:00:00 EST 2020
Control of cell death/survival balance by the MET dependence receptor.
eLife
Duplaquet L,Leroy C,Vinchent A,Paget S,Lefebvre J,Vanden Abeele F,Lancel S,Giffard F,Paumelle R,Bidaux G,Heliot L,Poulain L,Furlan A,Tulasne D
37-0100 was used in Western Blotting to shed light on new signaling mechanisms for dependence receptors' control of cell survival/death balance, which may offer new clues for the pathophysiology of epithelial structures.
Mon Feb 24 00:00:00 EST 2020
Identification of genomic and molecular traits that present therapeutic vulnerability to HGF-targeted therapy in glioblastoma.
Neuro-oncology
Sa JK,Kim SH,Lee JK,Cho HJ,Shin YJ,Shin H,Koo H,Kim D,Lee M,Kang W,Hong SH,Kim JY,Park YW,Song SW,Lee SJ,Joo KM,Nam DH
37-0100 was used in Western Blotting to provide an important framework for evaluating HGF-targeted therapy in future clinical settings.
Thu Feb 14 00:00:00 EST 2019
Genes co-amplified with ERBB2 or MET as novel potential cancer-promoting genes in gastric cancer.
Oncotarget
Kwon MJ,Kim RN,Song K,Jeon S,Jeong HM,Kim JS,Han J,Hong S,Oh E,Choi JS,An J,Pollack JR,Choi YL,Park CK,Shin YK
Published figure using c-Met monoclonal antibody (Product # 37-0100) in Western Blot
Fri Nov 03 00:00:00 EDT 2017
Development of a Novel c-MET-Based CTC Detection Platform.
Molecular cancer research : MCR
Zhang T,Boominathan R,Foulk B,Rao C,Kemeny G,Strickler JH,Abbruzzese JL,Harrison MR,Hsu DS,Healy P,Li J,Pi C,Prendergast KM,Hobbs C,Gemberling S,George DJ,Hurwitz HI,Connelly M,Garcia-Blanco MA,Armstrong AJ
37-0100 was used in flow cytometry to elucidate a unique c-MET-based CTC detection platform
Wed Jun 01 00:00:00 EDT 2016
Defective DNA single-strand break repair is responsible for senescence and neoplastic escape of epithelial cells.
Nature communications
Nassour J,Martien S,Martin N,Deruy E,Tomellini E,Malaquin N,Bouali F,Sabatier L,Wernert N,Pinte S,Gilson E,Pourtier A,Pluquet O,Abbadie C
370100 was used in western blot to study the DNA damage response in senescent epithelial cells
Fri Jan 29 00:00:00 EST 2016
MET is required for the recruitment of anti-tumoural neutrophils.
Nature
Finisguerra V,Di Conza G,Di Matteo M,Serneels J,Costa S,Thompson AA,Wauters E,Walmsley S,Prenen H,Granot Z,Casazza A,Mazzone M
37-0100 was used in ELISA and western blot to report that MET is required for neutrophil chemoattraction and cytotoxicity in response to its ligand hepatocyte growth factor.
Thu Jun 18 00:00:00 EDT 2015
MET is required for the recruitment of anti-tumoural neutrophils.
Nature
Finisguerra V,Di Conza G,Di Matteo M,Serneels J,Costa S,Thompson AA,Wauters E,Walmsley S,Prenen H,Granot Z,Casazza A,Mazzone M
37-0100 was used in ELISA and western blot to report that MET is required for neutrophil chemoattraction and cytotoxicity in response to its ligand hepatocyte growth factor.
Thu Jun 18 00:00:00 EDT 2015
H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b.
Oncotarget
Vennin C,Spruyt N,Dahmani F,Julien S,Bertucci F,Finetti P,Chassat T,Bourette RP,Le Bourhis X,Adriaenssens E
37-0100 was used in western blot to characterize enhancement of tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b by H19 non coding RNA-derived miR-675
Tue Oct 06 00:00:00 EDT 2015
Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST).
Oncotarget
Mahadevan D,Theiss N,Morales C,Stejskal AE,Cooke LS,Zhu M,Kurtzman D,Swart R,Ong E,Qi W
370100 was used in western blot to discuss the limitations of c-Kit/PDGFR-targeted therapies for treatment of gastrointestinal stromal tumors
Tue Feb 10 00:00:00 EST 2015
c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma.
Oncoimmunology
Kumai T,Matsuda Y,Ohkuri T,Oikawa K,Ishibashi K,Aoki N,Kimura S,Harabuchi Y,Celis E,Kobayashi H
37-0100 was used in Immunohistochemistry to study the expression and function of c-Met in NK/T-cell lymphoma cells, to elucidate its role.
Sun Feb 01 00:00:00 EST 2015
Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence.
Molecular oncology
Martin V,Corso S,Comoglio PM,Giordano S
37-0100 was used in western blot to study mechanisms underlying resistance to MET monoclonal antibodies and chemical tyrosine kinase inhibitors.
Mon Dec 01 00:00:00 EST 2014
Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence.
Molecular oncology
Martin V,Corso S,Comoglio PM,Giordano S
37-0100 was used in western blot to study mechanisms underlying resistance to MET monoclonal antibodies and chemical tyrosine kinase inhibitors.
Mon Dec 01 00:00:00 EST 2014
Gene silencing of c-Met leads to brain metastasis inhibitory effects.
Clinical & experimental metastasis
Lee SJ,Seol HJ,Lee HW,Kang WY,Kang BG,Jin J,Jo MY,Jin Y,Lee JI,Joo KM,Nam DH
37-0100 was used in immunohistochemistry - frozen section and western blot to investigate the role of c-Met in brain metastasis and test its potential as a preventive and/or therapeutic target in this disease.
Tue Oct 01 00:00:00 EDT 2013
Senescent fibroblasts enhance early skin carcinogenic events via a paracrine MMP-PAR-1 axis.
PloS one
Malaquin N,Vercamer C,Bouali F,Martien S,Deruy E,Wernert N,Chwastyniak M,Pinet F,Abbadie C,Pourtier A
37-0100 was used in Western Blotting to investigate whether the senescent fibroblast secretome has an impact on the initial stages of carcinogenesis.
Tue Dec 17 00:00:00 EST 2013
Identification of prognostic biomarkers for glioblastomas using protein expression profiling.
International journal of oncology
Jung Y,Joo KM,Seong DH,Choi YL,Kong DS,Kim Y,Kim MH,Jin J,Suh YL,Seol HJ,Shin CS,Lee JI,Kim JH,Song SY,Nam DH
37-0100 was used in immunohistochemistry - paraffin section to identify diagnostic and prognostic markers for glioblastoma
Sun Apr 01 00:00:00 EDT 2012
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Lennerz JK,Kwak EL,Ackerman A,Michael M,Fox SB,Bergethon K,Lauwers GY,Christensen JG,Wilner KD,Haber DA,Salgia R,Bang YJ,Clark JW,Solomon BJ,Iafrate AJ
Published figure using c-Met monoclonal antibody (Product # 37-0100) in Immunofluorescence
Tue Dec 20 00:00:00 EST 2011
Detection of hepatocyte growth factor (HGF) ligand-c-MET receptor activation in formalin-fixed paraffin embedded specimens by a novel proximity assay.
PloS one
Dua R,Zhang J,Parry G,Penuel E
37-0100 was used in Western Blotting to develop an alternative, novel approach to measure receptor activation by detecting and quantifying ligand-receptor complexes in formalin-fixed paraffin embedded specimens.
Fri Jan 21 00:00:00 EST 2011
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
Cancer research
Seiwert TY,Jagadeeswaran R,Faoro L,Janamanchi V,Nallasura V,El Dinali M,Yala S,Kanteti R,Cohen EE,Lingen MW,Martin L,Krishnaswamy S,Klein-Szanto A,Christensen JG,Vokes EE,Salgia R
Published figure using c-Met monoclonal antibody (Product # 37-0100) in Immunohistochemistry
Wed Apr 01 00:00:00 EDT 2009
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
Cancer research
Seiwert TY,Jagadeeswaran R,Faoro L,Janamanchi V,Nallasura V,El Dinali M,Yala S,Kanteti R,Cohen EE,Lingen MW,Martin L,Krishnaswamy S,Klein-Szanto A,Christensen JG,Vokes EE,Salgia R
Published figure using c-Met monoclonal antibody (Product # 37-0100) in Immunohistochemistry
Wed Apr 01 00:00:00 EDT 2009
Prognostic significance of c-Met expression in glioblastomas.
Cancer
Kong DS,Song SY,Kim DH,Joo KM,Yoo JS,Koh JS,Dong SM,Suh YL,Lee JI,Park K,Kim JH,Nam DH
370100 was used in immunohistochemistry - paraffin section to test if c-Met expression is associated with overall survival and tumor invasiveness in patients with glioblastomas
Thu Jan 01 00:00:00 EST 2009
Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer.
Cancer research
Kang JY,Dolled-Filhart M,Ocal IT,Singh B,Lin CY,Dickson RB,Rimm DL,Camp RL
Sat Mar 01 00:00:00 EST 2003
Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer.
Cancer research
Kang JY,Dolled-Filhart M,Ocal IT,Singh B,Lin CY,Dickson RB,Rimm DL,Camp RL
Sat Mar 01 00:00:00 EST 2003
Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer.
Cancer research
Kang JY,Dolled-Filhart M,Ocal IT,Singh B,Lin CY,Dickson RB,Rimm DL,Camp RL
Sat Mar 01 00:00:00 EST 2003
Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.
Cancer
Tolgay Ocal I,Dolled-Filhart M,D'Aquila TG,Camp RL,Rimm DL
Tue Apr 15 00:00:00 EDT 2003
